CG Oncology (CGON) EBIT Margin (2023 - 2026)
CG Oncology's (CGON) quarterly EBIT Margin came in at 6130.1% in Q1 2026, up 7503144.0% YoY from N/an in Q1 2025, and down 192.28% on a QoQ basis from 2097.33% in Q4 2025.
Powered by 
Analysis
CG Oncology (CGON) EBIT Margin (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of EBIT Margin data on file, last reported at 6130.1% in Q1 2026.
- Quarterly EBIT Margin rose 7503144.0% year-over-year to 6130.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4238.99% (up 1606328.0% YoY) and the FY2025 annual result came in at 4722.13%, up 534512.0% from the prior year.
- EBIT Margin retreated to 6130.1% in Q1 2026, from 2097.33% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 2097.33% in Q4 2025 to a low of 1935500.0% in Q4 2023.
- A 4-year average of 208244.27% and a median of 8344.08% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin surged 192715592 bps — and 2025, when it tumbled 7691409 bps.
- Tracing CGON's EBIT Margin over 4 years: stood at 1935500.0% in 2023, then surged by 100 bps to 8344.08% in 2024, then surged by 75 bps to 2097.33% in 2025, then plunged by 192 bps to 6130.1% in 2026.
- The last three EBIT Margin figures came in at 6130.1% (Q1 2026), 2097.33% (Q4 2025), and 3068.97% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | CG Oncology | 6.60 Bn | 6.60 Bn | -2.77 Mn | -7,467.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,467.68% |
| Mar 31, 2026 | -6,130.10% |
| Dec 31, 2025 | -2,097.33% |
| Sep 30, 2025 | -3,068.97% |
| Mar 31, 2025 | -81,161.54% |
| Dec 31, 2024 | -8,344.08% |
| Sep 30, 2024 | -65,802.33% |
| Jun 30, 2024 | -23,290.99% |
| Mar 31, 2024 | -4,247.45% |
| Dec 31, 2023 | -1,935,500.00% |
| Sep 30, 2023 | -156,033.33% |
| Mar 31, 2023 | -5,010.82% |